Therapy Protocol
177Lu-PSMA therapy – 150 to 200 mCi
Lutetium-177 PSMA radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC).
Dose: 150-200 mCi
Indication: Prostate Cancer
Clinical Overview & Mechanism
177Lu-PSMA radioligand therapy is a revolutionary theranostic treatment for advanced Metastatic Castration-Resistant Prostate Cancer.
Have questions about this therapy?
Book a consultation with Dr. Nikunj Jain for personalized treatment planning and expert guidance.